Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Myeloid 2Genitourinary 2Gastrointestinal 2Thoracic 1Sarcoma 1Plasma cell 1Dermatologic 1CNS 1

Conditions

Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1

Interventions

Nivolumab 24pembrolizumab 22Ipilimumab 17Specimen Handling 15Magnetic Resonance Spectroscopy 9CTLA-4 Antigen 8Opdualag 7relatlimab 6Cyclophosphamide 6binimetinib 5Paclitaxel 5trametinib 4fludarabine phosphate 4fludarabine 4cemiplimab 4Carboplatin 4Biopsy 4lifileucel 3dabrafenib 3atezolizumab 3X-Rays 3Taxes 3Standard of Care 3Radiotherapy 3Radiation 3Pemetrexed 3Introns 3Interferon alpha-2 3Immunoglobulin G 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Photons × Dermatologic × 30 days × Clear all
NCT03017820 2026-05-28

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
99 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡